Opinion

Video

Safety Outcomes with Leuprolide

Author(s):

Paul Sieber, MD

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Related Content
      FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
      May 29th 2025

      FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer

      Hannah Clarke
      The company plans to submit a Biologics License Application to the FDA at the end of 2026.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
      May 21st 2025

      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

      Hannah Clarke
      The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
      May 20th 2025

      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

      Hannah Clarke
      The phase 3 study design will now be submitted for final review by the agency.
      Study shows value of precision-based approaches in prostate cancer
      May 19th 2025

      Study shows value of precision-based approaches in prostate cancer

      Hannah Clarke
      The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
      © 2025 MJH Life Sciences

      All rights reserved.